Statin Articles

Articles
Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bétrisey S, Haller ML, Efthimiou O, et al.
Journal:
J Am Heart Assoc

First published: February 7, 2024 DOI: 10.1161/JAHA.123.030714
View
- Share
Articles
Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
Nicholls SJ, Nelson AJ, Lincoff AM, et al.
Journal:
JAMA Cardiol

First published: January 17, 2024 DOI: 10.1001/jamacardio.2023.5155
View
- Share
Articles
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu L, Orringer C, Catapano AL
Journal:
Eur Heart J

First published: December 28, 2023 DOI: 10.1093/eurheartj/ehad837
View
- Share
Articles
Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use
Drexel H, Mader A
Journal:
Cardiology

First published: November 21, 2023 DOI: 10.1159/000535372
View
- Share
Articles
Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial
Lee B, Hong SJ, Rha SW, et al.
Journal:
Atherosclerosis

First published: November 10, 2023 DOI: 10.1016/j.atherosclerosis.2023.117373
View
- Share
Articles
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance
Ridker PM, Lei L, Louie MJ, et al.
Journal:
Circulation

First published: November 6, 2023 DOI: 10.1161/CIRCULATIONAHA.123.066213
View
- Share
Articles
Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance
Bays HE, Bloedon LT, Lin G, et al.
Journal:
J Clin Lipidol

First published: October 31, 2023 DOI: 10.1016/j.jacl.2023.10.011
View
- Share
Articles
Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013–2020
Zheutlin AR, Jacobs JA, Derington CG, et al.
Journal:
J Clin Lipidol

First published: August 12, 2023 DOI: 10.1016/j.jacl.2023.08.005
View
- Share
Articles
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi E, Casula M, Cicero AFG, et al.
Journal:
Pharmacol Ther

First published: August 9, 2023 DOI: 10.1016/j.pharmthera.2023.108507
View
- Share
Articles
Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial
Lee SJ, Cha JJ, Choi WG, et al.
Journal:
JAMA Cardiol

First published: August 2, 2023 DOI: 10.1001/jamacardio.2023.2222
View
- Share
Articles
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen SE, Menon V, Nicholls SJ, et al.
Journal:
JAMA

First published: June 24, 2023 DOI: 10.1001/jama.2023.9696
View
- Share
Articles
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis
Lee SH, Lee YJ, Heo JH, et al.
Journal:
J Am Coll Cardiol

First published: April 3, 2023 DOI: 10.1016/j.jacc.2023.02.007
View
- Share

1 2 3 4

Statin Articles

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Articles

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial

Nicholls SJ, Nelson AJ, Lincoff AM, et al.

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Articles

Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance

Ridker PM, Lei L, Louie MJ, et al.

Articles

Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance

Bays HE, Bloedon LT, Lin G, et al.

Articles

Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013–2020

Zheutlin AR, Jacobs JA, Derington CG, et al.

Articles

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Raschi E, Casula M, Cicero AFG, et al.

Articles

Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial

Lee SJ, Cha JJ, Choi WG, et al.

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Articles

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis

Lee SH, Lee YJ, Heo JH, et al.

Articles

Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bétrisey S, Haller ML, Efthimiou O, et al.

Share

Articles

Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial

Nicholls SJ, Nelson AJ, Lincoff AM, et al.

Share

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Share

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Share

Articles

Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Lee B, Hong SJ, Rha SW, et al.

Share

Articles

Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance

Ridker PM, Lei L, Louie MJ, et al.

Share

Articles

Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance

Bays HE, Bloedon LT, Lin G, et al.

Share

Articles

Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013–2020

Zheutlin AR, Jacobs JA, Derington CG, et al.

Share

Articles

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events

Raschi E, Casula M, Cicero AFG, et al.

Share

Articles

Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial

Lee SJ, Cha JJ, Choi WG, et al.

Share

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Share

Articles

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis

Lee SH, Lee YJ, Heo JH, et al.

Share